Immunologic Agents : Immunomodulators
IPEGA3 “Pegasys injection” 180 mcg/syringe
IPEGA4 “Pegasys injection” 135 mcg/syringe
適應症：治療慢性B型肝炎，對於沒有肝硬化的病人以及有代償功能的肝硬化病人，珮格西施適合用來治療HBeAg陽性或HBeAg陰性，有病毒複製和肝臟發炎證據之慢性B型肝炎。治療慢性C型肝炎：單獨或合併RIBAVIRIN使用的珮格西施，適合用來治療沒有肝硬化的病人以及有代償功能的肝硬化病人之慢性C型肝炎
Usual dose:
Chronic hepatitis C, monotherapy: SC, 180 mcg qw for 48 wks.
Chronic hepatitis C, combination: SC, 180 mcg qw for 48 wks in combination with oral ribavirin 800 mg/day in 2 divided doses.
Chronic active type B viral hepatitis, monotherapy: 180 mcg qw for 48 wks.
Dose adjustment:
Renal failure: ESRD p’ts requiring hemodialysis should receive 135 mcg/wk for 48 wk.
Adverse effect:
Common: alopecia, injection site inflammation, injection site reaction, pruritus, myalgia, headache, insomnia, anxiety, irritability, fatigue, fever, influenza-like illness, rigor.
Serious: angina, cardiac dysrhythmia, diabetes mellitus, colitis, gastrointestinal hemorrhage, pancreatitis, peptic ulcer disease, anemia, aplastic anemia, neutropenia, thrombocytopenia, thrombotic thrombocytopenic purpura, abnormal liver function, cholangitis, fatty liver, autoimmune disease, myositis, cerebral hemorrhage, peripheral neuropathy, corneal ulcer, aggressive behavior, depression, psychotic disorder, suicide, pulmonary embolism, at risk for relapse, drug abuse/overdose, coma, infectious disease.
健保使用規範：健保藥品給付規定第八章免疫製劑。
通則四 (二)6.治療白血病使用之interferon alfa至多攜回二週。
通則四 (二)18.慢性病毒性Ｂ型肝炎、慢性病毒性C型肝炎所使用之長效型干擾素或短效型干擾素，其攜回之數量，至多為四週之使用量。